Migraine

Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives.

Condition(s) Type of Drug Phase Add-On Placebo Duration Open-Label Extension
Pediatric episodic migraine, under 15 days per month Approved Emgality monthly injection III Yes 50% 3 months 3 months
Pediatric chronic migraine, 15 or more days per month Approved Emgality monthly injection III Yes 50% 3 months 3 months
Pediatric episodic migraine abortive therapy Approved Reyvow oral drug III Yes 50% 24 weeks
Pediatric chronic migraine abortive therapy Approved Revyow oral drug III Yes 50% for 3 months, then 0% for 9 months 12 months

Response Form

If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!

Joshua A. Tobin, MD, Director of Migraine Research
Stephen S. Flitman, MD, Medical Director

Your Name
Name of Patient
Email Address
Your Telephone
Best Time to Call
Comments
 Ready?